These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2962009)

  • 1. Serum haloperidol concentration and choreiform movements in Huntington's disease.
    Barr AN; Fischer JH; Koller WC; Spunt AL; Singhal A
    Neurology; 1988 Jan; 38(1):84-8. PubMed ID: 2962009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].
    Giménez-Roldán S; Mateo D
    Neurologia; 1989 Oct; 4(8):282-7. PubMed ID: 2534679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
    J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea.
    Piolti R; Appollonio I; Perego M; Pozzi C; Rovati L; Ferrarese C; Frattola L
    Eur Neurol; 1995; 35(6):344-8. PubMed ID: 8591802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gait abnormality of Huntington's disease.
    Koller WC; Trimble J
    Neurology; 1985 Oct; 35(10):1450-4. PubMed ID: 3162109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor.
    Corsini GU; Onali P; Masala C; Cianchetti C; Mangoni A; Gessa G
    Arch Neurol; 1978 Jan; 35(1):27-30. PubMed ID: 145840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl)].
    Candelise L
    Riv Patol Nerv Ment; 1976; 96(1):54-62. PubMed ID: 134449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea.
    Leonard DP; Kidson MA; Brown JG; Shannon PJ; Taryan S
    Aust N Z J Psychiatry; 1975 Jun; 9(2):115-8. PubMed ID: 125578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of chorea in Huntington's disease by power spectral analysis.
    Weitzman DO; Rosfnfeld C; Korenyl C; Whittier JR
    Dis Nerv Syst; 1976 May; 37(5):264-8. PubMed ID: 131027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease.
    Girotti F; Carella F; Scigliano G; Grassi MP; Soliveri P; Giovannini P; Parati E; Caraceni T
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):848-52. PubMed ID: 6147393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of amantadine and haloperidol in Huntington's chorea.
    Saran BM; Klein MS; Benay EM
    J Clin Psychiatry; 1980 Jun; 41(6):221. PubMed ID: 6445900
    [No Abstract]   [Full Text] [Related]  

  • 13. Dyskinesia analysis. Histogram analysis of cineseismograms of human dyskinesia.
    Korenyi C; Whittier JR
    Dis Nerv Syst; 1974 Apr; 35(4):169-71. PubMed ID: 17894112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homovanillic acid and prolactin in Huntington's disease.
    Markianos M; Panas M; Kalfakis N; Vassilopoulos D
    Neurochem Res; 2009 May; 34(5):917-22. PubMed ID: 18841471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C; Hunter C; Davidson A; Jankovic J
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved gas chromatographic-mass spectrometric assay for haloperidol utilizing ammonia chemical ionization and selected-ion monitoring.
    Szczepanik-van Leeuwen PA
    J Chromatogr; 1985 May; 339(2):321-30. PubMed ID: 3159744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cerebrospinal fluid choline levels in patients with Huntington's chorea. Negative effect of haloperidol treatment.
    Consolo S; Ladinsky H; Bianchi S; Caraceni T
    Arch Psychiatr Nervenkr (1970); 1977 May; 223(3):265-70. PubMed ID: 142461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.